Pioneering Intranasal Delivery of mRNA, Antibodies, and Biologics to Unlock New Therapeutic Possibilities

• New small biologics fit for nasal delivery & biophysical attributes
• Demonstration of preclinical efficacy of inhaled biological antivirals
• Impact on mucosal immunity

Speakers:

Olivier Kitten

Founder & Chief Executive Officer

Affilogic